Cargando…
Biotech in China 2021, at the beginning of the 14th five-year period (“145”)
ABSTRACT: As China assumes a more and more dominant role in global science, this mini-review attempts to provide a bird’s eye view on how the bio-digital revolution impacts China’s biosciences and bioindustry. Triggered by top-down political programs and the buildup of an impressive infrastructure i...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088835/ https://www.ncbi.nlm.nih.gov/pubmed/33937929 http://dx.doi.org/10.1007/s00253-021-11317-8 |
_version_ | 1783686919197032448 |
---|---|
author | Schmid, Rolf D. Xiong, Xin |
author_facet | Schmid, Rolf D. Xiong, Xin |
author_sort | Schmid, Rolf D. |
collection | PubMed |
description | ABSTRACT: As China assumes a more and more dominant role in global science, this mini-review attempts to provide a bird’s eye view on how the bio-digital revolution impacts China’s biosciences and bioindustry. Triggered by top-down political programs and the buildup of an impressive infrastructure in science, information technology, and education, China’s biomedical and MedTech industries prosper. Plant and animal breeding programs transform agriculture and food supply as much as the Internet of things, and synthetic biology offers new opportunities for the manufacturing of specialty chemicals within the Chinese version of a “bioeconomy.” It is already becoming apparent that the new five-year period “145” (2021–2025) will further emphasize emission control, bioenvironmental protection, and more supply of biomass-derived energy. This review identifies key drivers in China’s government, industry, and academia behind these developments and details many access points for deeper studies. KEY POINTS: Biotechnology in China. Biomedical technology. New five-year period. |
format | Online Article Text |
id | pubmed-8088835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80888352021-05-03 Biotech in China 2021, at the beginning of the 14th five-year period (“145”) Schmid, Rolf D. Xiong, Xin Appl Microbiol Biotechnol Mini-Review ABSTRACT: As China assumes a more and more dominant role in global science, this mini-review attempts to provide a bird’s eye view on how the bio-digital revolution impacts China’s biosciences and bioindustry. Triggered by top-down political programs and the buildup of an impressive infrastructure in science, information technology, and education, China’s biomedical and MedTech industries prosper. Plant and animal breeding programs transform agriculture and food supply as much as the Internet of things, and synthetic biology offers new opportunities for the manufacturing of specialty chemicals within the Chinese version of a “bioeconomy.” It is already becoming apparent that the new five-year period “145” (2021–2025) will further emphasize emission control, bioenvironmental protection, and more supply of biomass-derived energy. This review identifies key drivers in China’s government, industry, and academia behind these developments and details many access points for deeper studies. KEY POINTS: Biotechnology in China. Biomedical technology. New five-year period. Springer Berlin Heidelberg 2021-05-03 2021 /pmc/articles/PMC8088835/ /pubmed/33937929 http://dx.doi.org/10.1007/s00253-021-11317-8 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Mini-Review Schmid, Rolf D. Xiong, Xin Biotech in China 2021, at the beginning of the 14th five-year period (“145”) |
title | Biotech in China 2021, at the beginning of the 14th five-year period (“145”) |
title_full | Biotech in China 2021, at the beginning of the 14th five-year period (“145”) |
title_fullStr | Biotech in China 2021, at the beginning of the 14th five-year period (“145”) |
title_full_unstemmed | Biotech in China 2021, at the beginning of the 14th five-year period (“145”) |
title_short | Biotech in China 2021, at the beginning of the 14th five-year period (“145”) |
title_sort | biotech in china 2021, at the beginning of the 14th five-year period (“145”) |
topic | Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088835/ https://www.ncbi.nlm.nih.gov/pubmed/33937929 http://dx.doi.org/10.1007/s00253-021-11317-8 |
work_keys_str_mv | AT schmidrolfd biotechinchina2021atthebeginningofthe14thfiveyearperiod145 AT xiongxin biotechinchina2021atthebeginningofthe14thfiveyearperiod145 |